UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **August 24, 2016**

CARDAX, INC.
(Exact name of registrant as specified in its charter)

Delaware	**333-181719**	**45-4484428**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2800 Woodlawn Drive, Suite 129, Honolulu, Hawaii 96822
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(808) 457-1400**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

ITEM 7.01 REGULATION FD DISCLOSURE.

Cardax, Inc. (the "Company") announced today that it has launched its first commercial product, ZanthoSyn™. ZanthoSyn™ is marketed as a novel astaxanthin dietary supplement with superior absorption and purity. The Company will use e-commerce as its primary marketing channel for ZanthoSyn™ through its website www.zanthosyn.com.

Astaxanthin is a clinically studied ingredient with safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, and liver health. The form of astaxanthin utilized by the Company in ZanthoSyn™ has demonstrated excellent safety in peer-reviewed published studies and is designated as GRAS (Generally Recognized as Safe) according to FDA regulations.

Our ZanthoSyn™ product manufacturing process relies on certain third-party suppliers and this dependence creates several risks, including limited control over pricing, availability, quality, and delivery schedules. In addition, any supply interruption could materially harm our ability to manufacture ZanthoSyn™ until a new source of supply is obtained on acceptable terms. We may be unable to find such other sources in a reasonable time period or on commercially reasonable terms, if at all, which would have an adverse effect on our business, financial condition and results of operations.

In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in the exhibits hereto are deemed to be "furnished" and shall not be deemed to be "filed" for purposes of the Exchange Act. The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Safe Harbor

This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No.	Description
99.1	Press Released Dated August 24, 2016 (furnished herewith)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 24, 2016

CARDAX, INC.

By: */s/ David G. Watumull*
David G. Watumull
Chief Executive Officer and President

Cardax Launches First Product ZanthoSyn™

Safe Anti-Inflammatory for General Health*

August 24, 2016 8:00 AM Eastern Daylight Time

HONOLULU—(BUSINESS WIRE)—Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today that it has launched its first commercial product, ZanthoSyn™, a safe anti-inflammatory for general health.

ZanthoSyn™ is a novel astaxanthin dietary supplement with superior absorption and purity, and is available through Cardax's commercial website, www.zanthosyn.com.

Astaxanthin is a clinically studied ingredient with safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, and liver health.* The form of astaxanthin utilized in ZanthoSyn™ has demonstrated excellent safety in peer-reviewed published studies and is designated as GRAS (Generally Recognized as Safe) according to FDA regulations.

Superior Absorption. In a head-to-head human study against a leading microalgal astaxanthin dietary supplement, ZanthoSyn™ provided 2.85 times more absorption ($p = 0.013$)—defined as the total amount of astaxanthin measured in the bloodstream over a 24-hour period following a single 24 mg dose. This means that two 12 mg capsules of ZanthoSyn™ deliver nearly the same amount of astaxanthin to the blood stream as six 12 mg capsules of microalgal astaxanthin. This study was sponsored by Cardax and led by Dr. Jon L. Ruckle, Cardax's lead medical advisor since 2013. Dr. Ruckle was the former Medical Director of the Covance Clinical Research Unit in Honolulu and has been a principal investigator of more than 350 clinical trials.

"These results demonstrate a highly significant and clinically meaningful advantage for ZanthoSyn," concluded Dr. Ruckle. "We were also pleased to see very consistent subject-to-subject absorption profiles."

Purity. ZanthoSyn™ contains pure astaxanthin prepared by natural product total synthesis. In contrast, the astaxanthin extracted from microalgae is obtained in a complex mixture, which may include many unknown microalgal by-products. The precision of synthetic manufacturing also provides healthcare professionals and health-conscious consumers with confidence in the quality and consistency of dosing from every capsule. ZanthoSyn™ is manufactured in accordance with current Good Manufacturing Practice (cGMP) regulations for dietary supplements.

"We are very pleased to launch this exciting product," said David G. Watumull, President and CEO of Cardax. "Our team includes leading astaxanthin experts and is uniquely positioned to lead the roll-out of our commercialization strategy over the next several quarters."

"Based on astaxanthin's published safety and efficacy data together with the superior absorption and purity of ZanthoSyn, I strongly recommend ZanthoSyn to those seeking a safe anti-inflammatory for their general health needs," added Dr. Jon L. Ruckle.

*** These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.**

About Cardax

Cardax devotes substantially all of its efforts to developing safe anti-inflammatory dietary supplements and drugs. Cardax is initially focusing on astaxanthin, which is a powerful and safe naturally occurring anti-inflammatory without the side effects of currently marketed anti-inflammatories. The safety and efficacy of Cardax's products have not been directly evaluated in clinical trials or confirmed by the FDA.

Safe Harbor

This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

For additional information, please contact:

Janice Kam
1-808-457-1400
press@cardaxpharma.com